Get To Know Us

Bruce Forest, M.D.

Bruce Forest, M.D.

Scientific Advisory Board Member

Bruce Forrest, MD, has over 30 years’ of global leadership experience in pharmaceutical development, with extensive expertise in vaccines and biopharmaceuticals development in both major and emerging markets. He currently serves as a scientific advisor to companies leveraging his understanding of the pharmaceutical industry, banking and financing, and organizational alignment to drive success. He was previously divisional Senior Vice President at Pfizer and prior at Wyeth Pharmaceuticals where he led clinical activities supporting the market authorization for RotaShield® (EU), Prevnar® (Global), and FluMist®. Dr. Forrest holds BS and MD degrees from the University of Adelaide and an MBA from the University of Warwick.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.